Verma Deepti, Agarwal Kiran, Tudu Sanjeev Kumar
Department of Histopathology, Dr Lal Path Labs, New Delhi, India.
Department of Pathology, Lady Hardinge Medical College, New Delhi, India.
Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):31-38. doi: 10.4103/IJPM.IJPM_393_16.
(1) The objective is to study the immunohistochemical expression of Breast cancer type 1 (BRCA1) in breast carcinoma on trucut biopsy specimens and (2) To relate its expression with that of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2)/neu and the clinicopathological parameters.
A cross-sectional hospital-based study was performed in Lady Hardinge Medical College and Shrimati Sucheta Kriplani Hospital, New Delhi, with collaboration of the Departments of Pathology and Surgery from the period of November 2008 to March 2010.
The study group included 54 cytologically proven cases of breast carcinoma. The immunohistochemical expression of BRCA1 was studied and related with expression of ER, PR, and HER-2/neu on their trucut biopsies.
The altered expression of BRCA1 (i.e., reduced or absent expression) was seen in 44.4% cases of breast carcinoma while 55.6% had positive expression. About 83% of breast carcinomas with altered BRCA1 expression were larger than 3 cm in size. The breast carcinomas showing altered expression were found to be mostly high grade (63.6%). This was statistically significant. The ER and PR negativity were seen in 62.5% and 79.2% breast carcinomas with altered BRCA1 expression, respectively. The score 3 positivity of HER-2/neu was more common among carcinomas with altered BRCA1 expression (21% vs. 16.7%). The triple negativity was found in 41.7% breast carcinomas having altered BRCA1 expression. This was statistically significant.
The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu and clinicopathological details may be helpful in predicting the individuals more likely to carry BRCA1 mutations and thus selecting the candidate and family members for genetic screening for BRCA1 mutations.
（1）研究1型乳腺癌（BRCA1）在粗针活检标本中的免疫组化表达情况；（2）将其表达与雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER-2）/neu的表达以及临床病理参数相关联。
在新德里哈丁夫人医学院和苏切塔·克里普拉尼夫人医院进行了一项基于医院的横断面研究，于2008年11月至2010年3月期间与病理科和外科合作开展。
研究组包括54例经细胞学证实的乳腺癌病例。研究了BRCA1的免疫组化表达，并将其与粗针活检中ER、PR和HER-2/neu的表达相关联。
44.4%的乳腺癌病例中观察到BRCA1表达改变（即表达降低或缺失），而55.6%呈阳性表达。BRCA1表达改变的乳腺癌中约83%大小大于3 cm。表达改变的乳腺癌大多为高级别（63.6%）。这具有统计学意义。BRCA1表达改变的乳腺癌中，ER和PR阴性分别见于62.5%和79.2%。HER-2/neu评分3阳性在BRCA1表达改变的癌中更常见（21%对16.7%）。BRCA1表达改变的乳腺癌中41.7%为三阴性。这具有统计学意义。
BRCA1、ER、PR和HER-2/neu的免疫组化表达与临床病理细节相结合，可能有助于预测更可能携带BRCA1突变的个体，从而为BRCA1突变的基因筛查选择候选者及其家庭成员。
Zotero 插件